BSGM Share Price | BioSig Technologies, Inc. Stock Analysis & Recommendation

Q: How big is BioSig Technologies, Inc.?

Market Cap: As of Jun 18, BioSig Technologies, Inc. has a market capitalization of 180.96 million, classified as a Micro Cap.Recent Quarterly Performance: For the latest four quarters, the company reported net sales of 0.02 million and a net profit of -9.72 million.Balance Sheet Snapshot: As of Dec 24, the company's shareholder's funds were -1.44 million, and total assets amounted to 0.84 million.

Q: What does BioSig Technologies, Inc. do?

Overview:BioSig Technologies, Inc. is a commercial-stage medical device company in the Pharmaceuticals & Biotechnology industry, focusing on biomedical signal processing technology for electrophysiology studies and cardiac procedures.Financial Snapshot:Most recent Net Profit: -3 Million (Quarterly Results - Mar 2025)Market cap: USD 180.96 Million (Micro Cap)Key Metrics:P/E: NA (Loss Making)Industry P/E: NADividend Yield: 0.00%Debt Equity: -1.35Return on Equity: -458.82%Price to Book: 66.78Contact Details:Address: 54 WILTON ROAD, 2ND FLOOR, WESTPORT CT : 06880Tel: 1 203 4095444Website: https://biosigtech.com/

Q: Is BioSig Technologies, Inc. technically bullish or bearish?

As of 14 July 2025, the technical trend for BioSig Technologies, Inc. has changed from bullish to mildly bullish. The current stance is mildly bullish, supported by daily moving averages indicating bullish momentum, while weekly MACD and KST show mildly bearish signals. Bollinger Bands are bullish across both weekly and monthly time frames. However, the Dow Theory indicates a mixed view with weekly mildly bullish and monthly mildly bearish signals. In terms of performance, the stock has significantly outperformed the S&P 500 with a year-to-date return of 329.53% compared to the S&P 500's 12.22%, and a one-year return of 1911.95% versus 17.14%.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

4.12 M

Shareholding (Sep 2025)

FII

0.85%

Held by 11 FIIs

DII

94.47%

Held by 6 DIIs

Promoter

0.00%

How big is BioSig Technologies, Inc.?

22-Jun-2025

As of Jun 18, BioSig Technologies, Inc. has a market capitalization of 180.96 million, with recent net sales of 0.02 million and a net profit of -9.72 million. The company's shareholder's funds were -1.44 million, and total assets amounted to 0.84 million.

View full answer

What does BioSig Technologies, Inc. do?

22-Jun-2025

BioSig Technologies, Inc. is a medical device company specializing in biomedical signal processing technology for electrophysiology and cardiac procedures. As of March 2025, it has a market cap of $180.96 million and reported a net profit loss of $3 million.

View full answer

Who are in the management team of BioSig Technologies, Inc.?

22-Jun-2025

As of March 2022, the management team of BioSig Technologies, Inc. includes Kenneth Londoner (CEO and Executive Chairman), Jeffrey O'Donnell (Lead Independent Director), Anthony Zook, Andrew Filler, Donald Foley, and Patrick Gallagher (all Independent Directors). They oversee the company's strategic direction and operations.

View full answer

Is BioSig Technologies, Inc. technically bullish or bearish?

20-Sep-2025

As of July 14, 2025, BioSig Technologies, Inc. shows a mildly bullish trend with strong daily moving averages and significant outperformance against the S&P 500, despite mixed signals from Dow Theory and weekly MACD indicators.

View full answer

Compare BioSig Technologies, Inc. with Similar Stocks

Neuronetics, Inc.Sonendo, Inc.Delcath Systems, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 167 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

1.61

Return on Equity

182.45%

Price to Book

-24.43

Revenue and Profits:

Net Sales:

(Quarterly Results - Sep 2025)

Net Profit:

-16 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-55.71%

6 Months

-75.16%

1 Year

141.27%

2 Years

189.93%

3 Years

87.06%

4 Years

32.5%

5 Years

-96.59%

BioSig Technologies, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

0.20%

EBIT Growth (5y)

7.66%

EBIT to Interest (avg)

-32.25

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.35

Sales to Capital Employed (avg)

0.01

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

48.90%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

-24.43

EV to EBIT

-5.10

EV to EBITDA

-5.48

EV to Capital Employed

-8.74

EV to Sales

156.42

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

Negative BV

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Bullish

Dow Theory

Mildly Bearish

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 4 Schemes (4.68%)

Foreign Institutions

Held by 11 Foreign Institutions (0.85%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Jun 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Sep 2025 is 23.53% vs -628.57% in Jun 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Jun'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-4.60",
          "val2": "-19.80",
          "chgp": "76.77%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-10.20",
          "val2": "-0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-15.60",
          "val2": "-20.40",
          "chgp": "23.53%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs -100.00% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 64.11% vs -5.13% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-12.40",
          "val2": "-28.20",
          "chgp": "56.03%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "2.30",
          "val2": "-0.20",
          "chgp": "1,250.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-10.30",
          "val2": "-28.70",
          "chgp": "64.11%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-315,225.00%",
          "val2": "-1,584,000.00%",
          "chgp": "1,26,877.50%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ

Sep'25

Jun'25

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-4.60

-19.80

76.77%

Interest

0.00

Exceptional Items

-10.20

-0.00

Consolidate Net Profit

-15.60

-20.40

23.53%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Jun 2025

Consolidated Net Profit

QoQ Growth in quarter ended Sep 2025 is 23.53% vs -628.57% in Jun 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-12.40

-28.20

56.03%

Interest

0.00

Exceptional Items

2.30

-0.20

1,250.00%

Consolidate Net Profit

-10.30

-28.70

64.11%

Operating Profit Margin (Excl OI)

-315,225.00%

-1,584,000.00%

1,26,877.50%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs -100.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 64.11% vs -5.13% in Dec 2023

All Annual Results

Company CV

About BioSig Technologies, Inc.

BioSig Technologies, Inc.

Pharmaceuticals & Biotechnology

BioSig Technologies, Inc. is a commercial-stage medical device company. The Company is commercializing biomedical signal processing technology platform to extract information from physiologic signals. The Company focuses on providing intracardiac signal information to electrophysiologists during electrophysiology (EP) studies and cardiac catheter ablation procedures for atrial fibrillation (AF) and ventricular tachycardia (VT). The Company is engaged in developing the Precise Uninterrupted Real-time evaluation of Electrograms (PURE) electro-pneumatic (EP) System, a surface electrocardiogram and intracardiac multichannel recording and analysis system that acquires, processes and displays electrocardiogram and electrograms required during electrophysiology studies and ablation procedures. The PURE EP System is a signal acquisition and processing technology.

Company Coordinates

Company Details

54 WILTON ROAD, 2ND FLOOR , WESTPORT CT : 06880

Tel: 1 203 4095444

https://biosigtech.com/

Registrar Details